EICHOR
● Completed
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)
Condition: Carcinoma, Nonsquamous Non-small-cell Lung · Sponsor: Merck Sharp & Dohme LLC
About this study
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, versus (vs) pembrolizumab plus maintenance pemetrexed for the treatment of non-squamous NSCLC. The study's 2 primary hypotheses are: 1. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent clinical review (BICR) and 2. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to overall survival (OS).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (178)
| Alabama Oncology Bruno Cancer Center ( Site 0001) | Birmingham, Alabama, United States | — |
| Northwest Alabama Cancer Center, PC ( Site 0002) | Muscle Shoals, Alabama, United States | — |
| Disney Family Cancer Center ( Site 0005) | Burbank, California, United States | — |
| Boca Raton Regional Hospital ( Site 0018) | Boca Raton, Florida, United States | — |
| Mid-Florida Cancer Centers ( Site 0022) | Orange City, Florida, United States | — |
| Moffitt Cancer Center ( Site 0024) | Tampa, Florida, United States | — |
| Columbus Regional Research Institute ( Site 0098) | Columbus, Georgia, United States | — |
| Mount Sinai Hospital Medical Center ( Site 0032) | Chicago, Illinois, United States | — |
| Oncology of Northshore ( Site 0033) | Rolling Meadows, Illinois, United States | — |
| Methodists Hospitals/Premier Oncology Hematology Associates ( Site 0036) | Merrillville, Indiana, United States | — |
| Medstar Good Samaritan Hospital ( Site 0040) | Baltimore, Maryland, United States | — |
| Barbara Ann Karmanos Cancer Institute ( Site 0041) | Detroit, Michigan, United States | — |
+ 166 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03976323